Claudette Falato
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial results.
Journal: NPJ breast cancer
Published: March 27, 2025
Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 30, 2024
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.
Journal: Nature communications
Published: September 18, 2023
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 04, 2023
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis.
Journal: ESMO open
Published: February 16, 2023
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer.
Journal: Cancer treatment reviews
Published: October 03, 2022
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 20, 2022
Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?
Journal: Cancer treatment reviews
Published: February 15, 2022
Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT).
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 15, 2021
Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials.
Journal: BMC cancer
Published: March 26, 2021
Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry.
Journal: Breast cancer research and treatment
Published: August 17, 2018
Last Updated: 09/26/2026